Clostridium Difficile - part 2

Clostridium difficile (C. diff) infection presents a clinical spectrum ranging from mild diarrhea to fulminant disease characterized by toxic megacolon, organ failure, and potential mortality. Pathogenesis is primarily driven by Enterotoxin A and Cytotoxin B, with severity influenced by host immune responses and specific bacterial strains like ribotype O27. Effective management necessitates the immediate discontinuation of causative broad-spectrum antibiotics, such as carbapenems and later-generation cephalosporins, whenever clinically feasible. While oral Vancomycin and Fidaxomicin are the primary therapeutic agents, Fidaxomicin demonstrates superior efficacy in reducing the high 25% recurrence rate, despite its higher cost. Metronidazole is no longer recommended for first-line therapy due to poor colonic absorption. For fulminant cases, aggressive treatment involves high-dose Vancomycin—administered orally, via nasogastric tube, or rectally—combined with intravenous Metronidazole and early surgical consultation for potential colectomy.